The strong Q1 beat and raised EPS guidance reinforce confidence in the FY26 outlook. Watch for continued margin expansion from the Transformation Office and order trends in the next quarter. The Polymem divestiture removes a drag, but the $13.8M loss on sale is a one-time item. The reiterated organic revenue guidance suggests management sees sustained demand.
Price Chart
Executive Summary
Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%. The company reiterated FY26 organic revenue growth guidance of 9%-13% and raised adjusted EPS guidance to $1.97-$2.05. The Polymem divestiture and Transformation Office launch signal a focus on margin expansion, but the $13.8M loss on sale and ongoing restructuring charges temper the headline beat.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $194M, up 15% YoY as reported and 11% organic
- Adjusted EPS of $0.48 vs consensus $0.38, a 26.3% beat
- GAAP EPS of $0.15 vs $0.10 YoY; GAAP operating margin expanded to 8.2% from 3.9%
- Adjusted operating margin of 15.4% vs 13.8% YoY, expanding 160 bps
- FY26 guidance reiterated: organic revenue growth 9%-13% ($803M-$833M); adjusted EPS raised to $1.97-$2.05
- Polymem divestiture closed March 30, 2026, generating a $13.8M loss on sale
- Transformation Office launched for site rationalization and margin optimization
- Cash and marketable securities of $785M at quarter end, up from $768M at Dec 2025
Financial Impact
Q1 revenue beat consensus by ~$1.8M (0.9%); adjusted EPS beat by $0.10 (26.3%). FY26 adjusted EPS guidance raised by ~$0.04 at midpoint vs prior.
Risk Factors
- FY26 guidance assumes 9%-13% organic growth; any macro or bioprocessing demand slowdown could pressure results
- Transformation Office restructuring costs may weigh on near-term margins
- Foreign exchange headwinds (~3% impact on reported revenue in Q1) could persist
- China partnership is early-stage; execution risk in APAC expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205011 |
| Document: 0001193125-26-205011-index.html | 0001193125-26-205011 |
| Document: 0001193125-26-205011.txt | 0001193125-26-205011 |
| 8-K Data (Synthetic) | 0001193125-26-205011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | S-4 | $181.69 $184.53 | ▲ +1.56% | ▲ +0.59% | $183.85 (+1.19%) |
Jul 28, 2026 9w ago | 8-K | $145.34 $181.69 | ▲ +25.01% | ▲ +21.63% | $183.85 (+26.49%) |
Jul 22, 2026 10w ago | 425 / 8-K | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $183.85 (+31.23%) |
Jul 22, 2026 10w ago | Press Release | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $183.85 (+31.23%) |
Jun 11, 2026 16w ago | Institutional Cluster | $130.59 $144.24 | ▲ +10.45% | ▲ +8.67% | $183.85 (+40.78%) |
May 5, 2026 21w ago | 8-K | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $183.85 (+46.36%) |
May 5, 2026 21w ago | Press Release | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $183.85 (+46.36%) |
Apr 22, 2026 23w ago | Press Release | $124.40 $108.52 | ▼ −12.77% | ▼ −15.93% | $183.85 (+47.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access